Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amifostine Regimens in Nasopharyngeal Carcinoma
NCT01762514Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2013
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of amifostine in xerostomia, mucositis and myelosuppression (6 arms), sponsored by Sun Yat-sen University. Primary endpoints: Effect on improving myelosuppression at 3 months, Effect on improving xerostomia at 3 months and 1 more. Status: unknown.
02
Drugs
amifostine
03
Conditions
xerostomiamucositismyelosuppression
Beyond the preview
Go deeper on NCT01762514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01762514.